Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fundació Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau operates within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This activity is localized within 1 distinct art unit and is assigned to 1 distinct examiner, reflecting a very narrow prosecution focus for the institution's current research output.
The busiest examiner for the institution is SOROUSH, LAYLA, who is responsible for 1 busiest examiner pending action. This single matter represents the entirety of the current prosecution pipeline. For practitioners, this indicates that the immediate success of the portfolio's biotechnology filings depends on navigating the specific review process of this one examiner in a single art unit. The concentrated nature of this work requires a deep understanding of the examiner's past decisions and the specific technical standards of the art unit involved in pharmaceutical review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855996 | TREATMENT OF MUSCLE FIBROSIS | SOROUSH, LAYLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855996 | TREATMENT OF MUSCLE FIBROSIS | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18855996 | TREATMENT OF MUSCLE FIBROSIS | SOROUSH, LAYLA | 1622 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFundació Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla Soroush has the most, with 1 of Fundació Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
